MEDIA_REFRESH_DATA_PRESS_RELEASE
Media
U.S. News Room
Press Releases
Mon Dec 14 00:00:00 GMT-05:00 2020
TROPION-Lung05 Phase 2 Trial of Datopotamab Deruxtecan Initiated in Patients with Advanced or Metastatic NSCLC with Actionable Genomic Alterations
Download
Mon Dec 14 00:00:00 GMT-05:00 2020
TROPION-Lung01 Head-to-Head Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan Versus Docetaxel in Previously Treated Patients with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Download
Thu Dec 10 00:00:00 GMT-05:00 2020
Results from First Combination Trial of ENHERTU® and Immune Checkpoint Inhibitor in Patients with HER2 Expressing Metastatic Breast Cancer Presented at the 2020 San Antonio Breast Cancer Symposium
Download
Thu Dec 10 00:00:00 GMT-05:00 2020
ENHERTU® Continues to Demonstrate Durable Responses with New Data from DESTINY-Breast01 in HER2 Positive Metastatic Breast Cancer
Download
Tue Nov 17 00:00:00 GMT-05:00 2020
Daiichi Sankyo to Present New Data for HER2 and HER3 Directed DXd ADCs at SABCS
Download
Thu Nov 12 00:00:00 GMT-05:00 2020
Daiichi Sankyo Creates New Business Unit to Unify Major Oncology Markets into One Streamlined Organization Dedicated to Patients with Cancer
Download
Mon Nov 02 00:00:00 GMT-05:00 2020
DESTINY-Breast05 Head-to-Head Phase 3 Trial of ENHERTU® Versus T-DM1 Initiated in Patients with HER2 Positive Early Breast Cancer at High Risk After Neo-adjuvant Therapy
Download
Wed Oct 28 00:00:00 GMT-05:00 2020
ENHERTU® Granted Priority Review in the U.S. for Treatment of HER2 Positive Metastatic Gastric Cancer
Download
Thu Oct 22 00:00:00 GMT-05:00 2020
Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated Regulatory T Cells
Download
Fri Sep 25 00:00:00 GMT-05:00 2020
ENHERTU® Approved in Japan for the Treatment of Patients with HER2 Positive Metastatic Gastric Cancer
Download